TED HENDERSON
Ted is Schooner Capital’s Chief Executive Officer. A Managing Partner, Ted allocates time to internal management and firm strategy while serving as a director at Brixton Biosciences and SRS Medical. Over the past several decades, Ted invested primarily in venture-stage companies, guiding Schooner’s migration back to its roots in direct investing. He led Schooner healthcare sector investments including Cartesian Therapeutics (NASDAQ:RNAC), Millstone Medical Outsourcing (acquired by Arlington Capital), 4G Clinical (Goldman Sachs Asset Management), Topokine Therapeutics (Allergan), Mimetogen Pharmaceuticals (Allergan), and Best Doctors (Brown Brothers). He also led investments in Seventh Generation (Unilever), Zixi (Clearwater Capital), MediaSilo (Marlin Equity), and StyleFeeder (Time Inc.). Ted is a past director at several not-for-profits and co-chaired Friends of Dartmouth Soccer. He has an MBA from Harvard Business School and graduated cum laude from Dartmouth College, studying Mandarin.
